...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Straightforward palladium-mediated synthesis and biological evaluation of benzo [j]phenanthridine-7,12-diones as anti-tuberculosis agents
【24h】

Straightforward palladium-mediated synthesis and biological evaluation of benzo [j]phenanthridine-7,12-diones as anti-tuberculosis agents

机译:直接钯介导的苯并介导的合成和生物学评价[J]菲啶-7,12-致抗结核病药剂

获取原文
获取原文并翻译 | 示例
           

摘要

In 1991, WHO recognized the resurgence of tuberculosis as a global health problem. Although modern chemotherapy is effective against the causative pathogen Mycobacterium tuberculosis, the current drug regimens have failed to eradicate the disease. The success of the pathogen, partially attributed to drug resistance, necessitates the development of novel anti-tuberculosis drugs. Benzo[j]phenanthridine-7,12-diones, tetracyclic derivatives of the natural product benz[g]isoquinoline-5,10-dione, were conveniently synthesized via palladium-catalyzed intramolecular cyclization of N-methanesulfonyl-3-bromo-2-(ary-lamino)methyl-1,4-naphthoquinones. Here we report on the bioactivity of eight benzo[j]phenanthridine-7,12-dione derivatives as candidate drug molecules against M. tuberculosis and on their cytotoxicity on C3A human hepatocytes. The strongest antimicrobial activity (as detected by growth inhibition of bacteria, using luminometry and BACTEC 460-TB) and lowest cytotoxicity was found for 3-methylbenzo [j]phenanthridine-7,12-dione 5e, which was also effective in targeting intracellular M. tuberculosis (in murine J774 macrophages) and was not genotoxic for C3A hepatocytes.
机译:1991年,谁认识到结核病作为全球健康问题的重新疗效。虽然现代化疗对致病病原体结核病有效,但目前的药物方案未能消除这种疾病。病原体的成功部分归因于耐药性,需要开发新型的抗结核药物。苯并[j]菲啶-7,12-二酮,通过钯催化的N-甲磺酰基-3- Bromo-2-通过钯催化的分子分子化方便地合成天然产物Benz [G]异喹啉-5,10-二酮的四环素衍生物。 (ARY-LAMINO)甲基-1,4-萘醌。在这里,我们报告了八苯并的生物活性[j]菲啶-7,12-二酮衍生物作为候选药物分子对抗肺癌的候选药物分子及其在C3a人肝细胞上的细胞毒性。对于3-甲基苯并[J]菲林-7,12-二酮5e,发现了最强的抗微生物活性(通过使用亮度测量和Bactec 460-Tb检测到细菌的生长抑制)和最低细胞毒性,这也是有效的靶向细胞内m 。结核病(在鼠J774巨噬细胞中),并不是C3A肝细胞的遗传毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号